Results · Apr-Jun 2026 · filed 6 Aug 2026
Emcure Pharmaceuticals Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 23% to ₹2,580 crore from ₹2,101 crore in Apr-Jun 2025.
Operating profit grew 28% to ₹532 crore, an operating margin of 20.6% (up 0.8 points from a year ago).
Net profit grew 36% to ₹292 crore from ₹215 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +4%, net profit +20%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 2,580 | 2,101 | +23% |
| Operating profit (EBITDA) | 532.5 | 416.8 | +28% |
| Operating margin | 20.6% | 19.8% | +0.8 pts |
| Net profit | 292.5 | 214.8 | +36% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 8 Aug 2026Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.